TScan Therapeutics (TCRX) Competitors

TScan Therapeutics (NASDAQ:TCRX) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, community ranking, earnings, valuation, institutional ownership and media sentiment.

Which has more risk & volatility, TCRX or RGNX?

TScan Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.

Does the media refer more to TCRX or RGNX?

In the previous week, REGENXBIO had 8 more articles in the media than TScan Therapeutics. MarketBeat recorded 11 mentions for REGENXBIO and 3 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.89 beat REGENXBIO's score of 0.62 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
REGENXBIO	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend TCRX or RGNX?

TScan Therapeutics currently has a consensus price target of $9.33, suggesting a potential upside of 512.02%. REGENXBIO has a consensus price target of $32.78, suggesting a potential upside of 311.57%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe TScan Therapeutics is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
REGENXBIO	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Does the MarketBeat Community favor TCRX or RGNX?

REGENXBIO received 403 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 83.33% of users gave TScan Therapeutics an outperform vote while only 65.53% of users gave REGENXBIO an outperform vote.

Company	Underperform	Outperform
TScan Therapeutics	Outperform Votes 40 83.33%	Underperform Votes 8 16.67%
REGENXBIO	Outperform Votes 443 65.53%	Underperform Votes 233 34.47%

Is TCRX or RGNX more profitable?

REGENXBIO has a net margin of -283.19% compared to TScan Therapeutics' net margin of -1,188.88%. TScan Therapeutics' return on equity of -58.72% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,188.88%	-58.72%	-36.02%
REGENXBIO	-283.19%	-70.65%	-41.68%

Which has stronger earnings & valuation, TCRX or RGNX?

TScan Therapeutics has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$2.82M	30.65	-$89.22M	-$1.15	-1.33
REGENXBIO	$83.33M	4.79	-$263.49M	-$4.61	-1.73

Do insiders and institutionals hold more shares of TCRX or RGNX?

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 2.8% of TScan Therapeutics shares are held by insiders. Comparatively, 13.1% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

TScan Therapeutics beats REGENXBIO on 10 of the 17 factors compared between the two stocks.